Efgartigimod PH20 SC PFS

BIOLOGICAL2 trials

Sponsors

argenx

Conditions

AChR-Ab Seropositive Generalized Myasthenia GravisGeneralized Myasthenia GravisGeneralized Myasthenia Gravis (gMG)MGMG - Myasthenia GravisMyasthenia GravisMyasthenia Gravis (MG)gMG

Phase 2

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

RecruitingNCT07673627

argenxAChR-Ab Seropositive Generalized Myasthenia Gravis, gMG, MG - Myasthenia Gravis +1

Start: 2026-07-10End: 2028-04-01Target: 40Updated: 2026-09-18

Unknown Phase

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

RecruitingNCT07294170

argenxAChR-Ab Seropositive Generalized Myasthenia Gravis, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG) +3

Start: 2025-12-19End: 2028-03-07Target: 70Updated: 2026-09-18